02342nas a2200193   4500008004100000245013600041210006900177260000800246520155600254100002301810700002401833700002501857700002301882700001901905700002801924700002501952700002301977856014802000       2017                        eng d00aSynthesis, antimycobacterial screening and molecular docking studies of 4-aryl-4′-methyl-2′-aryl-2,5′-bisthiazole derivatives0 aSynthesis antimycobacterial screening and molecular docking stud  cJUL3 aA series of 4-aryl-4′-methyl-2′-aryl-2,5′-bisthia- zole derivatives (5a–o) were synthesized and screened for inhibitory activity against Mycobacterium tuberculosis H37Ra (ATCC 25177) and Mycobacterium bovis BCG (ATCC 35743) strains. Five lead compounds (5e, 5f, 5g, 5h, and 5o) were further confirmed from their dose dependent effect against MTB and Bovine–Calmette–Guerin. The most promising compounds 5f (MIC90: 11.32 μg/mL), 5h (MIC90: 11.59 μg/mL), and 5o (MIC90: 23.64 μg/mL) showed strong antitubercular activity against dormant MTB and BCG as well as almost insignificant cytotoxicity up to 100μg/mL against HeLa, A549, and PANC-1 human cancer cell lines. Further, the synthesized compounds were found to have potential antibacterial activity against Gram-negative bac- teria, Escherichia coli, Pseudomonas flurescence and Gram- positive bacteria, Staphylococcus aureus, Bacillus subtilis. Most of the synthesized compounds showed moderateactivity against fungal strain Candida albicans. Molecular docking studies of these compounds showed significant interactions with crystal structure of the cytochrome P45014α-sterol demethylase (CYP51) PDB ID: 1E9X. Hydrogen bond interactions with SER261 and VAL395 are important interactions for selective inhibition of designed inhibitors. Compounds 5f, 5h, and 5o showed significant interactions with 1E9X. All the experimental results promote us to consider this series as a starting point for the devel- opment of novel, selective and more potent antitubercular agents in the future.1 aAbhale, Yogita, K.1 aShinde, Abhijit, D.1 aDeshmukh, Keshav, K.1 aNawale, Laxman, U.1 aSarkar, Dhiman1 aChoudhari, Prafulla, B.1 aKumbhar, Santosh, S.1 aMhaske, Pravin, C.  uhttps://library.ncl.res.in/content/synthesis-antimycobacterial-screening-and-molecular-docking-studies-4-aryl-4%E2%80%B2-methyl-2%E2%80%B2-aryl01775nas a2200265   4500008004100000022001400041245007300055210006900128260000800197300001400205490000700219520094900226653003101175653001701206653001301223653001401236100002301250700002401273700002601297700002001323700001901343700001901362700002301381856010501404       2019                        eng d  a0960-894X00aThiazolyl-pyrazole derivatives as potential antimycobacterial agents0 aThiazolylpyrazole derivatives as potential antimycobacterial age  cMAY  a1199-12020 v293 a<p>Mycobacterium tuberculosis (Mtb) is an obligate aerobe that is capable of long-term persistence under conditions of low oxygen tension. A series of thiazolyl-pyrazole derivatives (6a-f, 7a-f, 8c, 8e) were screened for antimycobacterial activity against dormant M. tuberculosis H37Ra (D-MTB) and M. bovis BCG (D-BCG). Nine thiazolyl- pyrazole analogs, 6c, 6e, 7a, 7b, 7c, 7e, 7f, 8c and 8e exhibited promissing minimum inhibitory concentration (MIC) values (0.20-28.25 mu g/mL) against D-MTB and D-BCG strains of Mtb. Importantly, six compounds (7a, 7b, 7e, 7f, 8c and 8e) exhibited excellent antimycobacterial activity and low cytotoxicity at the maximum evaluated concentration of &gt; 250 mu g/mL. Finally, the promising antimycobacterial activity and lower cytotoxicity profile suggested that, these compounds could be further subjected for optimization and development as a lead, which could have the potential to treat tuberculosis.</p>10aantimycobacterial activity10aCytotoxicity10aPyrazole10athiazoles1 aTakate, Sushma, J.1 aShinde, Abhijit, D.1 aKarale, Bhausaheb, K.1 aAkolkar, Hemant1 aNawale, Laxman1 aSarkar, Dhiman1 aMhaske, Pravin, C.  uhttps://library.ncl.res.in/content/thiazolyl-pyrazole-derivatives-potential-antimycobacterial-agents01555nas a2200253   4500008004100000022001400041245011200055210006900167520065400236653001500890653002700905653001700932653003100949653001400980653001300994100002701007700002301034700002401057700002401081700002301105700001901128700002201147856013201169       2022                        eng d  a1551-700400aSynthesis and antimycobacterial screening of a novel series of alpha-amino acids containing thiazole linker0 aSynthesis and antimycobacterial screening of a novel series of a3 a<p>
	A small focused library of uncommon (S)-2-amino-3-(4-(((4-methyl-2-arylthiazol-5-yl)methyl)amino)phenyl) propanoic acid (5a-e) and (S)-2-amino-3-(4-(((2-arylthiazol-4-yl)methyl)amino)phenyl)propanoic acid (9a-d) derivatives have been efficiently synthesized by employing molecular simplification. The title compounds were screened for inhibitory activity against Mycobacterium tuberculosis H37Ra (MTB) and Mycobacterium bovis (BCG) strains. The cytotoxicity study was conducted against primary Human Umbilical Vein Endothelial Cells (HUVECs), on two different human tumor cells HeLa, and HCT 116 and was observed non-toxic to host cells.</p>
10aAmino acid10aantibacterial activity10aCytotoxicity10aMycobacterium tuberculosis10asynthesis10aThiazole1 aNalawade, Jitendra, L.1 aMhaske, Pravin, C.1 aShinde, Abhijit, D.1 aChavan, Abhijit, P.1 aAbhale, Yogita, K.1 aSarkar, Dhiman1 aBobade, Vivek, D.  uhttps://library.ncl.res.in/content/synthesis-and-antimycobacterial-screening-novel-series-alpha-amino-acids-containing-thiazole